Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Non-metastatic
How would you discuss the prognosis of HR-positive early breast cancer in an elderly >90 patient who elects against surgery in favor of endocrine treatment only?
Any role of radiation in this setting?
Related Questions
How do you interpret the EBCTCG meta-analysis analyzing the magnitude of benefit of anthracyclines in early stage ER+ breast cancer?
In which scenarios do you use vaginal estrogen in patients with history of HR positive breast cancer?
What is your treatment approach in patients with early breast cancer with axillary soft tissue involvement, with or without concurrent lymph node involvement?
In a patient with ER+/HER2+ breast cancer with significant residual disease post neoadjuvant TCHP, is there a role of using CDK4/6i in the adjuvant setting with T-DM1?
Does HER2 status or response to neoadjuvant therapy influence your decision to use ovarian function suppression in premenopausal patients with ER+ HER2+ tumors?
In which patients do you offer adjuvant bisphosphates in breast cancer treatment?
Would you offer neoadjuvant chemoimmunotherapy per KEYNOTE 522 for a patient with clinical stage IIB triple-negative breast cancer with apocrine histology or recommend surgery first?
Are there any scenarios you would use CDK 4/6i to treat HR-positive HER2-positive breast cancer in combination with anti-HER2 agents?
Is there an increaed risk of cancer when using spironolactone in patients with hormone positive breast cancer?
Would you recommend axillary lymph node dissection in a pre-menopausal woman with ER+ PR+ HER2- IDC, s/p lumpectomy and SLN with pT1c pN1 cM0 disease, where 2 sentinel nodes are positive for macrometastasis and 1 SN is positive for micrometastasis?